Thresholds for normal blood pressure and serum cholesterol.
作者信息
Westin Steinar, Heath Iona
出版信息
BMJ. 2005 Jun 25;330(7506):1461-2. doi: 10.1136/bmj.330.7506.1461.
Abstract
摘要
相似文献
1
Thresholds for normal blood pressure and serum cholesterol.正常血压和血清胆固醇的阈值。
BMJ. 2005 Jun 25;330(7506):1461-2. doi: 10.1136/bmj.330.7506.1461.
2
3
[An epidemiological study of risk indicators for cardiovascular diseases (EPOZ). I. Blood pressure, serum cholesterol level, Quetelet-index and smoking habits in an open population aged 5 years and older].[心血管疾病风险指标的流行病学研究（EPOZ）。I. 5岁及以上开放人群的血压、血清胆固醇水平、体重指数和吸烟习惯]
Ned Tijdschr Geneeskd. 1980 Feb 9;124(6):183-9.
4
Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.根据个体的绝对心血管风险，使用药物降低血压和血液胆固醇。
Lancet. 2005;365(9457):434-41. doi: 10.1016/S0140-6736(05)17833-7.
5
Criteria for considering people at risk for cardiovascular disease prevention; guidelines of the Joint British Societies of cardiovascular disease in clinical practice.
Ann Clin Biochem. 2007 Mar;44(Pt 2):196. doi: 10.1258/000456307780117984.
6
7
A supermarket cardiovascular screening program: analysis of participants' solicitation of follow-up care.一项超市心血管筛查项目：参与者后续护理需求分析
Am J Prev Med. 1994 Sep-Oct;10(5):283-9.
8
Thresholds for conventional and home blood pressure by sex and age in 5018 participants from 5 populations.来自5个群体的5018名参与者按性别和年龄划分的常规血压和家庭血压阈值。
Hypertension. 2014 Oct;64(4):695-701. doi: 10.1161/HYPERTENSIONAHA.114.03839. Epub 2014 Jun 30.
9
Combined effects of systolic blood pressure and total cholesterol on cardiovascular disease risk.收缩压和总胆固醇对心血管疾病风险的联合作用。
Circulation. 2005 Nov 29;112(22):3373-4. doi: 10.1161/CIRCULATIONAHA.105.581934.
10
Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region.亚太地区收缩压和血清胆固醇对心血管疾病的联合影响。
Circulation. 2005 Nov 29;112(22):3384-90. doi: 10.1161/CIRCULATIONAHA.105.537472. Epub 2005 Nov 21.
引用本文的文献
1
How Genes Modulate Patterns of Aging-Related Changes on the Way to 100: Biodemographic Models and Methods in Genetic Analyses of Longitudinal Data.基因如何在迈向百岁人生的过程中调节衰老相关变化模式：纵向数据遗传分析中的生物人口统计学模型与方法
N Am Actuar J. 2016;20(3):201-232. doi: 10.1080/10920277.2016.1178588. Epub 2016 Jun 22.
2
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.运动与药物干预对死亡率影响的比较效果：元流行病学研究
Br J Sports Med. 2015 Nov;49(21):1414-22. doi: 10.1136/bjsports-2015-f5577rep.
3
How the effects of aging and stresses of life are integrated in mortality rates: insights for genetic studies of human health and longevity.衰老效应与生活压力如何体现在死亡率中：对人类健康和长寿基因研究的启示
Biogerontology. 2016 Feb;17(1):89-107. doi: 10.1007/s10522-015-9594-8. Epub 2015 Aug 18.
4
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.运动和药物干预对死亡率结局的比较效果：荟萃流行病学研究。
BMJ. 2013 Oct 1;347:f5577. doi: 10.1136/bmj.f5577.
5
Prevalence of polypharmacy and drug interaction among hospitalized patients: opportunities and responsabilities in pharmaceutical care.住院患者多重用药及药物相互作用的患病率：药学服务中的机遇与责任
Mater Sociomed. 2012;24(2):68-72. doi: 10.5455/msm.2012.24.68-72.
6
Big pharma: a story of success in a market economy.大型制药公司：市场经济中的成功故事。
Med Health Care Philos. 2013 May;16(2):305-9. doi: 10.1007/s11019-012-9384-x.
7
Genetic model for longitudinal studies of aging, health, and longevity and its potential application to incomplete data.衰老、健康和长寿纵向研究的遗传模型及其在不完整数据中的潜在应用。
J Theor Biol. 2009 May 7;258(1):103-11. doi: 10.1016/j.jtbi.2009.01.023. Epub 2009 Feb 4.
8
Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population.通过多种风险因素的组合能否充分识别出心血管疾病高风险个体？基于挪威HUNT 2人群的建模研究。
J Eval Clin Pract. 2009 Feb;15(1):103-9. doi: 10.1111/j.1365-2753.2008.00962.x.
9
Model of hidden heterogeneity in longitudinal data.纵向数据中的隐藏异质性模型。
Theor Popul Biol. 2008 Feb;73(1):1-10. doi: 10.1016/j.tpb.2007.09.001. Epub 2007 Sep 18.
10
The Quality and Outcomes Framework: what have you done to yourselves?质量与结果框架：你们对自己做了什么？
Br J Gen Pract. 2007 Jun;57(539):435-7.
本文引用的文献
1
Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study.临床实践中实施欧洲心血管疾病预防指南引发的伦理困境。一项描述性流行病学研究。
Scand J Prim Health Care. 2004 Dec;22(4):202-8. doi: 10.1080/02813430410006693.
2
Atenolol in hypertension: is it a wise choice?阿替洛尔用于治疗高血压：这是一个明智的选择吗？
Lancet. 2004;364(9446):1684-9. doi: 10.1016/S0140-6736(04)17355-8.
3
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.欧洲临床实践中心血管疾病预防指南。欧洲及其他学会心血管疾病预防临床实践联合工作组第三次报告
Eur Heart J. 2003 Sep;24(17):1601-10. doi: 10.1016/s0195-668x(03)00347-6.
4
Is opportunistic disease prevention in the consultation ethically justifiable?在诊疗过程中预防机会性疾病在伦理上是否合理？
BMJ. 2003 Aug 30;327(7413):498-500. doi: 10.1136/bmj.327.7413.498.
5
General practice workload implications of the national service framework for coronary heart disease: cross sectional survey.《国家冠心病服务框架对全科医疗工作量的影响：横断面调查》
BMJ. 2001 Aug 4;323(7307):269-70. doi: 10.1136/bmj.323.7307.269.
6
Preventing cardiovascular disease in primary care.在初级保健中预防心血管疾病。
BMJ. 2001 Aug 4;323(7307):246-7. doi: 10.1136/bmj.323.7307.246.
7
Open letter disputes WHO hypertension guidelines.公开信对世界卫生组织高血压指南提出质疑。
BMJ. 1999 Apr 3;318(7188):893B. doi: 10.1136/bmj.318.7188.893b.
8
Communicating the risk reduction achieved by cholesterol reducing drugs.传达降低胆固醇药物所实现的风险降低情况。
BMJ. 1998 Jun 27;316(7149):1956-8. doi: 10.1136/bmj.316.7149.1956.
Zotero 插件